Hospital
City Hospital, INC
City Hospital, INC was paid $41.06M by Medicaid between Jan 2018 and Dec 2024, across 454 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoCITY HOSPITAL, INC
MARTINSBURG, WV 25401
MARTINSBURG, WV 25401
33aNPI1457389249assigned 06/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$41.06M
24GClaims1,114,527
24DCodes billed454
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#7 of 26
Median peer was paid$18.33M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 193,129 | $9.06M | |
| 2019 | 119,836 | $5.42M | |
| 2020 | 221,032 | $8.77M | |
| 2021 | 207,029 | $5.40M | |
| 2022 | 109,186 | $3.44M | |
| 2023 | 134,757 | $4.39M | |
| 2024incomplete | 129,558 | $4.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 16,609 | 14,111 | $5.96M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 39,201 | 33,826 | $5.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.9% | 43,968 | 38,989 | $3.67M |
| 80053 | Comprehensive metabolic panel | 2.7% | 81,820 | 66,823 | $1.11M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 19,687 | 15,380 | $1.06M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 91,185 | 72,529 | $1.05M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 5,942 | 5,181 | $934K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 15,943 | 14,593 | $751K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 20,074 | 5,922 | $706K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 4,788 | 2,448 | $665K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 8,264 | 7,485 | $558K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 6,250 | 5,619 | $472K |
442 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.1% | 4,641 | $470K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 18,362 | $436K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,847 | $358K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 21,049 | $348K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,244 | $334K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,982 | $326K |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,762 | $300K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,228 | $285K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 29,994 | $282K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15,951 | $278K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,124 | $275K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,531 | $271K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,129 | $258K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,701 | $256K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,556 | $250K |
| 87631 | <1% | 2,508 | $247K | |
| 84484 | <1% | 18,922 | $247K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,562 | $242K |
| G0378 | Hospital observation service, per hour | <1% | 4,693 | $240K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,820 | $234K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,116 | $230K |
| 81001 | <1% | 22,409 | $223K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,202 | $217K |
| 83735 | <1% | 7,808 | $181K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,623 | $176K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 573 | $167K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,033 | $166K |
| 83690 | <1% | 15,325 | $163K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 143 | $163K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,246 | $162K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,306 | $161K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,937 | $153K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,108 | $153K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,104 | $153K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,887 | $150K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,549 | $149K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,694 | $148K |
| 81025 | <1% | 10,620 | $144K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,032 | $139K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,613 | $138K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 4,646 | $135K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 936 | $135K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,347 | $133K |
| 80061 | Lipid panel | <1% | 8,295 | $129K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 669 | $128K |
| 76830 | Ultrasound, transvaginal | <1% | 1,708 | $124K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,679 | $120K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,053 | $119K |
| 96376 | <1% | 3,706 | $119K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,484 | $117K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 340 | $113K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,177 | $109K |
| 81003 | <1% | 11,966 | $106K | |
| 93971 | <1% | 1,704 | $103K | |
| 71250 | <1% | 2,114 | $101K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,346 | $98K |
| 84702 | <1% | 6,615 | $97K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,873 | $96K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 580 | $95K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 512 | $93K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,651 | $93K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,522 | $93K |
| 85610 | <1% | 7,971 | $93K | |
| 96367 | <1% | 2,811 | $93K | |
| 0099U | <1% | 538 | $92K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,442 | $86K |
| 97162 | <1% | 1,859 | $85K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 752 | $82K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,878 | $81K |
| 86140 | <1% | 6,266 | $78K | |
| 76641 | <1% | 1,335 | $78K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,562 | $77K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,320 | $76K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,825 | $75K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 209 | $74K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 462 | $74K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 618 | $69K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,646 | $69K |
| 85027 | <1% | 3,982 | $69K | |
| 72131 | <1% | 1,025 | $67K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,050 | $66K |
| 87507 | <1% | 257 | $66K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 736 | $65K |
| 96415 | <1% | 895 | $64K | |
| 88304 | <1% | 947 | $64K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,631 | $64K |
| 82607 | <1% | 3,442 | $64K | |
| 86850 | <1% | 4,693 | $63K | |
| 95811 | <1% | 107 | $62K | |
| 93017 | <1% | 715 | $62K | |
| 76801 | <1% | 1,102 | $61K | |
| 80050 | General health panel | <1% | 1,563 | $61K |
| 97161 | <1% | 1,140 | $60K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,672 | $60K |
| 83880 | <1% | 2,932 | $59K | |
| 72141 | <1% | 319 | $58K | |
| 87653 | <1% | 1,731 | $58K | |
| 84439 | <1% | 3,670 | $57K | |
| 90837 | Psychotherapy session, about an hour | <1% | 601 | $57K |
| 82728 | <1% | 3,602 | $56K | |
| 80074 | <1% | 1,298 | $55K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,003 | $55K |
| 83605 | <1% | 3,416 | $55K | |
| 86901 | <1% | 4,908 | $54K | |
| 86900 | <1% | 4,902 | $52K | |
| 87040 | <1% | 2,763 | $52K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 834 | $51K |
| 64483 | <1% | 195 | $51K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 430 | $50K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,211 | $50K |
| 87186 | <1% | 3,909 | $49K | |
| 70486 | <1% | 608 | $48K | |
| 93975 | <1% | 427 | $47K | |
| 85730 | <1% | 4,098 | $45K | |
| 93970 | <1% | 459 | $43K | |
| 87340 | <1% | 2,185 | $42K | |
| 86803 | <1% | 2,247 | $42K | |
| 85007 | <1% | 2,231 | $42K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,266 | $40K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 515 | $40K |
| 64493 | <1% | 187 | $40K | |
| 87486 | <1% | 482 | $40K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 461 | $39K |
| 87581 | <1% | 481 | $39K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,336 | $39K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 232 | $38K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,634 | $38K |
| 84466 | <1% | 3,038 | $37K | |
| 76536 | <1% | 561 | $37K | |
| 59025 | Fetal non-stress test | <1% | 1,776 | $36K |
| 97113 | <1% | 995 | $36K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,578 | $35K |
| 88312 | <1% | 515 | $35K | |
| 0097U | <1% | 431 | $34K | |
| 86780 | <1% | 2,310 | $34K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,624 | $34K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,087 | $33K |
| 87070 | <1% | 2,100 | $33K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 773 | $32K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 856 | $32K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 701 | $31K |
| 82565 | <1% | 1,427 | $30K | |
| 73630 | <1% | 1,318 | $30K | |
| 84703 | <1% | 1,236 | $30K | |
| 85651 | <1% | 2,748 | $29K | |
| 94060 | <1% | 629 | $29K | |
| 10060 | <1% | 402 | $29K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,092 | $29K |
| 82746 | <1% | 1,529 | $27K | |
| 87077 | <1% | 2,355 | $27K | |
| 76775 | <1% | 497 | $27K | |
| 73130 | <1% | 1,039 | $27K | |
| 72110 | <1% | 939 | $27K | |
| 82550 | <1% | 1,932 | $26K | |
| 73564 | <1% | 1,006 | $26K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 1,100 | $26K |
| 96523 | <1% | 1,413 | $26K | |
| 85379 | <1% | 1,709 | $26K | |
| 83540 | <1% | 3,184 | $26K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,603 | $25K |
| 86706 | <1% | 1,045 | $25K | |
| 73610 | <1% | 1,047 | $24K | |
| 88142 | <1% | 1,391 | $24K | |
| 96417 | <1% | 355 | $24K | |
| 84145 | <1% | 1,366 | $24K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,761 | $23K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,230 | $23K |
| 86618 | <1% | 1,085 | $23K | |
| 84112 | <1% | 282 | $22K | |
| 81513 | <1% | 192 | $22K | |
| 74018 | <1% | 1,020 | $22K | |
| 97014 | <1% | 1,471 | $22K | |
| 90715 | <1% | 617 | $22K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,314 | $21K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,697 | $21K |
| 87210 | <1% | 1,431 | $21K | |
| 84100 | <1% | 1,868 | $21K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 13 | $21K |
| 73030 | <1% | 1,179 | $21K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 678 | $21K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,788 | $21K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 178 | $20K |
| 88307 | <1% | 239 | $20K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 41 | $20K |
| 83516 | <1% | 757 | $20K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,123 | $20K |
| 77066 | Tomosynthesis, mammo | <1% | 301 | $20K |
| 82570 | <1% | 1,977 | $20K | |
| 93271 | <1% | 247 | $19K | |
| 12001 | <1% | 230 | $19K | |
| 86255 | <1% | 619 | $18K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,017 | $18K |
| 87088 | <1% | 1,128 | $18K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 223 | $18K |
| 93925 | <1% | 162 | $17K | |
| 95806 | <1% | 297 | $17K | |
| 87641 | <1% | 639 | $17K | |
| 94729 | <1% | 410 | $16K | |
| 87205 | <1% | 1,492 | $16K | |
| 86038 | <1% | 864 | $16K | |
| 93320 | <1% | 233 | $16K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,444 | $16K |
| 76770 | <1% | 393 | $16K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,563 | $16K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 942 | $15K |
| Q3014 | Telehealth originating site facility fee | <1% | 698 | $15K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 303 | $15K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 842 | $14K |
| 93325 | <1% | 245 | $14K | |
| 84550 | <1% | 1,124 | $14K | |
| 73110 | <1% | 460 | $14K | |
| 82150 | <1% | 295 | $14K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,759 | $14K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 362 | $14K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,016 | $14K |
| 92557 | <1% | 654 | $13K | |
| 86762 | <1% | 723 | $13K | |
| 80076 | <1% | 1,111 | $13K | |
| 84153 | <1% | 487 | $13K | |
| 86308 | <1% | 801 | $12K | |
| 94726 | <1% | 377 | $12K | |
| 93978 | <1% | 114 | $12K | |
| 82784 | <1% | 562 | $12K | |
| 86431 | <1% | 636 | $12K | |
| 73502 | <1% | 551 | $12K | |
| 96411 | <1% | 231 | $12K | |
| 87147 | <1% | 922 | $12K | |
| 83615 | <1% | 911 | $12K | |
| 81329 | <1% | 83 | $12K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 91 | $12K |
| C1769 | Guide wire | <1% | 578 | $11K |
| 20610 | <1% | 128 | $11K | |
| 84156 | <1% | 1,029 | $11K | |
| 82043 | <1% | 1,099 | $11K | |
| 87481 | <1% | 391 | $11K | |
| 83970 | <1% | 395 | $11K | |
| 12011 | <1% | 154 | $11K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 184 | $11K |
| 87081 | <1% | 912 | $11K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 101 | $10K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 106 | $10K |
| 82803 | <1% | 381 | $10K | |
| 81596 | <1% | 128 | $10K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 141 | $10K |
| 87902 | <1% | 74 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,010 | $10K |
| 93976 | <1% | 116 | $10K | |
| 77002 | <1% | 190 | $10K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 115 | $9K |
| 76870 | <1% | 164 | $9K | |
| 84403 | <1% | 371 | $9K | |
| 29125 | <1% | 92 | $9K | |
| 82248 | <1% | 1,044 | $9K | |
| 70491 | <1% | 164 | $9K | |
| 82977 | <1% | 386 | $9K | |
| 86704 | <1% | 363 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,973 | $8K |
| 73221 | <1% | 105 | $8K | |
| 90671 | <1% | 470 | $8K | |
| 86480 | <1% | 150 | $8K | |
| 86003 | <1% | 88 | $8K | |
| 82950 | <1% | 895 | $8K | |
| 84520 | <1% | 1,158 | $8K | |
| 82140 | <1% | 238 | $7K | |
| 83883 | <1% | 250 | $7K | |
| 86790 | <1% | 250 | $7K | |
| 84146 | <1% | 330 | $7K | |
| 97116 | <1% | 490 | $7K | |
| 92567 | <1% | 1,167 | $7K | |
| 80069 | <1% | 591 | $7K | |
| 72100 | <1% | 218 | $6K | |
| 86376 | <1% | 342 | $6K | |
| 82172 | <1% | 216 | $6K | |
| 83010 | <1% | 219 | $6K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 125 | $6K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 788 | $6K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 206 | $6K |
| 82247 | <1% | 545 | $6K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 343 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 123 | $6K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 14 | $6K |
| 93798 | <1% | 715 | $5K | |
| 82272 | <1% | 268 | $5K | |
| 73140 | <1% | 180 | $5K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 154 | $5K |
| 86787 | <1% | 389 | $5K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 256 | $5K |
| 95813 | <1% | 25 | $5K | |
| 84460 | <1% | 370 | $5K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 573 | $5K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 255 | $5K |
| 92587 | <1% | 132 | $5K | |
| 82010 | <1% | 599 | $5K | |
| 72040 | <1% | 184 | $5K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 667 | $4K |
| 83655 | <1% | 229 | $4K | |
| 92551 | <1% | 589 | $4K | |
| 73560 | <1% | 209 | $4K | |
| 88185 | <1% | 49 | $4K | |
| 86200 | <1% | 83 | $4K | |
| 36600 | <1% | 98 | $4K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 246 | $4K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 57 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 25 | $4K |
| 71271 | <1% | 72 | $4K | |
| 73562 | <1% | 307 | $4K | |
| 93270 | <1% | 246 | $3K | |
| 81015 | <1% | 584 | $3K | |
| 95800 | <1% | 136 | $3K | |
| 27096 | <1% | 12 | $3K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 92 | $3K |
| 82105 | <1% | 99 | $3K | |
| 97164 | <1% | 84 | $3K | |
| 93923 | <1% | 55 | $3K | |
| 93225 | <1% | 54 | $3K | |
| 83001 | <1% | 142 | $3K | |
| 90686 | <1% | 220 | $3K | |
| C1729 | Catheter, drainage | <1% | 60 | $2K |
| 70496 | <1% | 58 | $2K | |
| 72072 | <1% | 103 | $2K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 36 | $2K |
| 59430 | <1% | 27 | $2K | |
| 93226 | <1% | 54 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 34 | $2K |
| 49083 | <1% | 33 | $2K | |
| 84165 | <1% | 124 | $2K | |
| 74178 | <1% | 13 | $2K | |
| 94664 | <1% | 116 | $2K | |
| 90723 | <1% | 253 | $2K | |
| 97165 | <1% | 45 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 41 | $2K |
| 51798 | <1% | 413 | $2K | |
| 82103 | <1% | 28 | $2K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 45 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,050 | $2K |
| 73100 | <1% | 16 | $2K | |
| 97166 | <1% | 56 | $2K | |
| 92579 | <1% | 48 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,286 | $2K |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 126 | $2K |
| 80179 | <1% | 98 | $2K | |
| 88184 | <1% | 49 | $1K | |
| 86160 | <1% | 39 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 128 | $1K |
| 73090 | <1% | 60 | $1K | |
| 86920 | <1% | 31 | $1K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 16 | $1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 13 | $1K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 95 | $1K |
| 84450 | <1% | 196 | $1K | |
| 83002 | <1% | 56 | $1K | |
| 83520 | <1% | 52 | $1K | |
| 90656 | <1% | 243 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 147 | $1K |
| 87529 | <1% | 22 | $1K | |
| 72202 | <1% | 40 | $1K | |
| J3490 | Unclassified drugs | <1% | 6,116 | $1K |
| 73080 | <1% | 56 | $1K | |
| 72052 | <1% | 30 | $1K | |
| 90474 | <1% | 141 | $1K | |
| 72050 | <1% | 38 | $1K | |
| 74183 | <1% | 14 | $965.23 | |
| 86592 | <1% | 37 | $962.09 | |
| 74221 | <1% | 38 | $955.43 | |
| 90636 | <1% | 13 | $929.83 | |
| 90746 | <1% | 31 | $926.58 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,450 | $917.29 |
| 73590 | <1% | 56 | $915.12 | |
| 80164 | <1% | 62 | $912.98 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 29 | $880.36 |
| 80055 | <1% | 25 | $877.03 | |
| 84402 | <1% | 26 | $807.94 | |
| 80143 | <1% | 58 | $803.81 | |
| 80051 | <1% | 65 | $803.78 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 13 | $775.77 |
| 73700 | <1% | 12 | $758.84 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 13 | $751.20 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26 | $745.10 |
| 72114 | <1% | 33 | $716.20 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,217 | $714.26 |
| 76882 | <1% | 43 | $695.42 | |
| 82947 | <1% | 72 | $695.32 | |
| 82525 | <1% | 27 | $693.84 | |
| 90658 | <1% | 32 | $657.19 | |
| 86769 | <1% | 18 | $638.57 | |
| 84075 | <1% | 82 | $633.44 | |
| 90710 | <1% | 16 | $628.72 | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $601.13 |
| 82390 | <1% | 25 | $599.04 | |
| 97035 | <1% | 25 | $587.50 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 91 | $533.97 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 12 | $530.39 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 61 | $513.03 |
| 85018 | <1% | 151 | $511.33 | |
| 36592 | <1% | 16 | $480.00 | |
| 72081 | <1% | 18 | $476.97 | |
| 86677 | <1% | 17 | $458.98 | |
| 83021 | <1% | 27 | $450.22 | |
| 73070 | <1% | 13 | $425.74 | |
| 83020 | <1% | 27 | $416.27 | |
| 87807 | <1% | 15 | $400.83 | |
| G0010 | Administration of hepatitis b vaccine | <1% | 14 | $394.54 |
| 73620 | <1% | 39 | $347.54 | |
| 90680 | <1% | 85 | $301.65 | |
| 73600 | <1% | 140 | $240.90 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 89 | $237.57 |
| 77080 | <1% | 13 | $231.04 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 34 | $218.07 |
| 80178 | <1% | 12 | $207.92 | |
| 80306 | <1% | 29 | $196.94 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 258 | $164.48 |
| 88342 | <1% | 30 | $161.98 | |
| 94010 | <1% | 14 | $145.32 | |
| 90648 | <1% | 423 | $125.80 | |
| 82962 | <1% | 75 | $123.89 | |
| 96127 | <1% | 44 | $118.80 | |
| 70498 | <1% | 16 | $117.06 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 28 | $113.14 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 58 | $109.02 |
| 86705 | <1% | 25 | $108.76 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 15 | $85.79 |
| 85652 | <1% | 48 | $64.35 | |
| 36416 | <1% | 118 | $60.80 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 101 | $53.24 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 788 | $36.67 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 47 | $29.95 |
| 99173 | <1% | 13 | $28.22 | |
| 99459 | <1% | 66 | $25.00 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 102 | $14.11 |
| 99001 | <1% | 43 | $11.40 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 129 | $11.14 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 70 | $7.98 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 56 | $3.96 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 40 | $1.35 |
| J1815 | Injection, insulin, per 5 units | <1% | 33 | $0.56 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 62 | $0.00 |
| 90633 | 0% | 38 | $0.00 | |
| 90653 | 0% | 21 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 99172 | 0% | 109 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 39 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialQUINONES, KATHLEEN (VP OF FINANCE)
Parent organizationWEST VIRGINIA UNIVERSITY HOSPITALS EAST INC
| Provider | Location | Paid |
|---|---|---|
| Billings Clinic | Billings, MT | $53.85M |
| Jefferson Memorial Hospital | Ranson, WV | $21.65M |
| Billings Clinic | Billings, MT | $15.71M |
| Billings Clinic | Billings, MT | $3.32M |
| Billings Clinic | Billings, MT | $2.99M |
| Billings Clinic | Billings, MT | $2.40M |
| Billings Clinic | Cody, WY | $110K |
| Billings Clinic | Billings, MT | $97K |
| Billings Clinic | Billings, MT | $20K |
| Billings Clinic | Livingston, MT | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.